Ahmed Kotb/LinkedIn
Aug 18, 2025, 23:49
Ahmed Kotb: HHT Management—Choosing the Right Therapy?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“HHT management (guideline highlights):
- Epistaxis → Topical + Antifibrinolytics → Anti-angiogenic if refractory
- GI bleed → Grade by iron/RBC needs → (mild) → (moderate–severe)
- Anemia → Screen → Oral iron → IV iron.”
More on coagulation disorders featured in Hemostasis Today.
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT